Pharmaceutical Technology

MARCH 4, 2023

VE-800 is under clinical development by Vedanta Biosciences and currently in Phase II for Solid Tumor. VE-800 overview VE-800 is under development for the treatment of solid tumors including gastric/gastroesophageal junction adenocarcinoma, microsatellite-stable colorectal cancer and metastatic melanoma.

Bacteria 100

Bacteria Clinical Trials Clinical Trials Drugs 100

Pharmaceutical Technology

MARCH 4, 2023

VE-800 is under clinical development by Vedanta Biosciences and currently in Phase II for Solid Tumor. VE-800 overview VE-800 is under development for the treatment of solid tumors including gastric/gastroesophageal junction adenocarcinoma, microsatellite-stable colorectal cancer and metastatic melanoma.

Bacteria 100

Bacteria Clinical Trials Clinical Trials Drugs 100

Pharmaceutical Technology

MAY 31, 2023

Decoy-20 is under clinical development by Indaptus Therapeutics and currently in Phase I for Hepatocellular Carcinoma. It comprises of a single strain of killed and intact, non-pathogenic gram bacteria with reduced LPS-endotoxin activity. it is administered through intravenous route.

Drug Delivery Systems 100

Drug Delivery Systems Drug Delivery Bacteria Drugs 100

pharmaphorum

SEPTEMBER 28, 2021

VLA15 targets the outer surface protein A (OspA) of the Borrelia burgdorferi bacteria that causes Lyme disease, a tick-borne infection that causes a characteristic rash that can be accompanied by flu-like symptoms and – in some cases – debilitating tiredness and aches that can last for years.

Vaccination 105

Vaccination Vaccine Bacteria Protein 105

pharmaphorum

JUNE 20, 2022

Valneva is on the hook for 40% of development costs, up from 30%, but also stands to receive milestone payments of up to $100 million based on sales performance which were not included in the original agreement. The shot targets the outer surface protein A (OspA) of the Borrelia burgdorferi bacteria that causes Lyme disease.

Vaccination 98

Vaccination Vaccine Licensing Licensing 98

Outsourcing Pharma

SEPTEMBER 11, 2023

million seed funding round to develop its point-of-care diagnostic platform, which can confirm the presence of bacteria and rapidly identify effective antibiotics to use and which ones to avoid. Glasgow diagnostics spinout Microplate Dx has closed a Â2.5

Development 52

Development Bacteria Clinical Development 52

Pharmaceutical Technology

JUNE 6, 2023

The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress. Pharma Mar offers in vitro diagnostic products used for detection of virus and bacteria in respiratory infections and human papilloma virus genotypes, among others.

Hormones 100

Hormones In-Vitro Genotype Bacteria 100

pharmaphorum

SEPTEMBER 30, 2020

Funding will support completion of an ongoing phase 2 trial and further clinical development of VE303, an orally-administered live biotherapeutic product (LBP) consisting of eight bacterial strains designed to therapeutically reset a patient’s gut microbiota to stop C.

Bacteria 52

Bacteria Production Trials Clinical Development 52

XTalks

AUGUST 18, 2021

Also important are the environmental changes that take place in the lung tissue during infection with SARS-CoV-2; the buildup of fluid and pus in pulmonary alveoli can provide a hospitable breeding ground for pathogenic bacteria. This is consistent with autopsy reports from previous pandemics, including the influenza pandemic of 1918.

Development 105

Development Bacteria Drugs Vaccine 105

pharmaphorum

APRIL 26, 2022

There’s only one vaccine candidate for tick-borne infection Lyme disease in clinical development – Valneva and Pfizer’s VLA15 – and it has just moved another step closer to being available.

Vaccine 69

Vaccine Vaccination Bacteria Trials 69

The Pharma Data

MARCH 8, 2021

VLA15 is the only active Lyme disease vaccine candidate in clinical development today, and covers six serotypes that are prevalent in North America and Europe. OspA is one of the most dominant surface proteins expressed by the bacteria when present in a tick. About VLA 15. burgdorferi naïve volunteers. About Lyme Disease.

Vaccination 52

Vaccination Vaccine Bacteria Protein 52

Roots Analysis

FEBRUARY 27, 2024

The firm also has the right to obtain exclusive licenses to the Affimer proteins for clinical development and commercialization. How many of the ADCs in development have pyrrolobenzodiazepine (PBD) as warhead: Pyrrolobenzodiazepines are a class of compounds that kill cells by binding their DNA and interfering with replication.

Antibody 52

Antibody Licensing Licensing Contract Manufacturing 52

The Pharma Data

JANUARY 4, 2021

In addition, it has discovered and is developing the Outer Membrane Protein Targeting Antibiotics (OMPTA). OMPTA are potentially the first new class of antibiotics in clinical development in the last 50 years against Gram-negative bacteria.

Bacteria 52

Bacteria Development Containment Protein 52

The Pharma Data

APRIL 26, 2022

About VLA15 VLA15 is the only Lyme disease vaccine candidate currently in clinical development. This investigational multivalent protein subunit vaccine uses an established mechanism of action for a Lyme disease vaccine that targets the outer surface protein A (OspA) of Borrelia burgdorferi, the bacteria that cause Lyme disease.

Vaccination 52

Vaccination Vaccine Bacteria Protein 52

The Pharma Data

DECEMBER 21, 2020

22, 2020 (GLOBE NEWSWIRE) — Polyphor AG (SIX: POLN) today announced that the UK Medicines and Healthcare products regulatory agency (MHRA) has granted a CTA (Clinical Trial Authorization) to start the first-in-human Phase I study of its novel class antibiotic murepavadin, delivered via the oral inhalation route.

Clinical Trials 40

Clinical Trials Clinical Trials Trials Bacteria 40

Delveinsight

JULY 27, 2021

Seres was in a joint partnership with Nestlé Health Science (NHS) for development of different bacteria-based drugs, many of which are under clinical development. With another type of treatment already in the developing phase, there are still hopes for carrying the drug forward.

Vaccination 96

Vaccination Vaccine Trials Manufacturing 96

The Pharma Data

DECEMBER 13, 2020

In addition, it has discovered and is developing the Outer Membrane Protein Targeting Antibiotics (OMPTA). OMPTA are potentially the first new class of antibiotics in clinical development in the last 50 years against Gram-negative bacteria.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Bacteria 52

The Pharma Data

JULY 21, 2021

VLA15 is the only active Lyme disease vaccine candidate in clinical development today, and covers six serotypes that are prevalent in North America and Europe. OspA is one of the most dominant surface proteins expressed by the bacteria when present in a tick. The program was granted Fast Track designation by the U.S.

Vaccination 52

Vaccination Vaccine Trials Bacteria 52

Pfizer

FEBRUARY 16, 2023

While VLA15 is still under investigation, to date the companies have been encouraged by the data from the Phase 2 clinical studies, which demonstrated strong immunogenicity and acceptable safety and tolerability profiles. 2-4 About VLA15 VLA15 is the only Lyme disease vaccine candidate currently in clinical development.

Clinical Trials 76

Clinical Trials Clinical Trials Vaccination Vaccine 76

The Pharma Data

JULY 18, 2021

Pneumococcal disease is an infection caused by bacteria called Streptococcus pneumoniae, or pneumococcus. Different strains of this bacteria are called serotypes. Invasive pneumococcal disease (IPD) occurs when the bacteria infect parts of the body that are usually free from germs.

Immune Response 52

Immune Response Vaccine Vaccination FDA Approval 52

XTalks

APRIL 12, 2021

The last update on the clinical development of inzomelid came in December when a pharmacokinetic (PK) study initiated by Inflazome in early April was withdrawn by Roche, who attributed it to a “strategic decision by sponsor.”. According to Neuropore’s pipeline page, both UCB0599 and NPT520-34 remain in Phase I clinical development.

Gene Therapy 96

Gene Therapy Gene Trials Development 96

The Pharma Data

DECEMBER 2, 2020

Additionally, HZI is looking to develop a new treatment for difficult-to-treat Pseudomonas aeruginosa infections in cystic fibrosis patients. aeruginosa bacteria, instead of killing the bacteria as an antibiotic would aim to do. to establish a new joint venture company, Nanjing AuroRNA Biotech Co., in Mainland China.

Drugs 52

Drugs Gene Editing Genome Genomics 52

The Pharma Data

DECEMBER 13, 2020

The Nature Communications publication titled, “Immunotherapy with an engineered bacteria by targeting the STING pathway for anti-tumor immunity,” details the engineering and characterization of SYNB1891 (Leventhal, D.S., SYNB1891 is being evaluated in a Phase 1 clinical trial. Sokolovska, A.,

Immune Response 40

Immune Response Engineer Medicine Clinical Trials 40

The Pharma Data

OCTOBER 26, 2020

The Company has generated multiple clinical stage mAbs targeting bacteria that cause life-threatening infections such as ventilator associated pneumonia (VAP) and hospital acquired pneumonia (HAP), in addition to preclinical stage antiviral mAbs. The Company’s pipeline is highlighted below: Aridis’ Pipeline. AR-301 (VAP).

Antibody 52

Antibody Genetic Engineering Development Clinical Trials 52

The Pharma Data

OCTOBER 19, 2020

“Pneumococcal disease in adults is on the rise globally, in part driven by disease-causing serotypes not targeted by the currently available pneumococcal conjugate vaccine,” said Dr. Roy Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories. About Pneumococcal Disease.

Vaccination 52

Vaccination Vaccine Immune Response Containment 52

The Pharma Data

OCTOBER 14, 2020

Priothera will use the funds to progress the clinical development of mocravimod, a modulator of sphingosine 1 phosphate (S1P) receptors, to enhance the curative potential of allogeneic hematopoietic stem cell transplantation (HSCT) for treating AML. CARB-X will provide Polyphor with initial funding of up to $2.62

Clinical Trials 52

Clinical Trials Clinical Trials Manufacturing In-Vivo 52

The Pharma Data

OCTOBER 22, 2020

The Company intends to use the net proceeds from this offering to support its planned New Drug Application submission for oral sulopenem for the treatment of uncomplicated urinary tract infections in patients with quinolone-resistant pathogens, the continued clinical development of sulopenem, and for working capital and general corporate purposes.

In-Vitro 40

In-Vitro Clinical Trials Clinical Trials Clinical Development 40

The Pharma Data

OCTOBER 19, 2020

Caris Precision Oncology Alliance members also have access to the Caris Pharmatech oncology trial network, which can help reduce the time it takes to identify and connect appropriate patients with novel targeted cancer therapies in clinical development.

Life Science 52

Life Science Clinical Trials Clinical Trials RNA 52

The Pharma Data

DECEMBER 15, 2020

Anokion is responsible for preclinical activities and Phase I clinical development of partnered programs, and Bristol Myers Squibb will fund subsequent trials and commercial activities at clinical proof-of-concept. Patient Recruitment.

Clinical Trials 52

Clinical Trials Clinical Trials Antibody Trials 52

XTalks

AUGUST 2, 2023

2) Botox Therapeutic/Cosmetic Botox, or botulinum neurotoxin, is a neurotoxic protein produced by the Clostridium botulinum bacteria. In partnership with Seagen, Sanofi will design, develop and commercialize ADCs for three cancer targets using Sanofi’s proprietary monoclonal antibody technology and Seagen’s proprietary ADC technology.

Sales 98

Sales Manufacturing FDA Approval Life Science 98

pharmaphorum

DECEMBER 15, 2020

Proceeds will advance the clinical development of MinervaX’s novel GBS vaccine through phase 2 clinical trials, as well as manufacturing and regulatory preparation for phase 3. These are capable of mobilising the immune system against GBS bacteria and preventing invasion of epithelial and endothelial cell barriers.

Bacteria 52

Bacteria Vaccine Vaccination Immune Response 52

XTalks

DECEMBER 24, 2020

Omer maintains that the solution to this challenge is something that’s already in practice by developers of the mRNA vaccines. What you do is you insist that a proper clinical development program is followed and that has been followed with trial data of tens of thousands of people,” says Dr. Omer.

Life Science 111

Life Science Vaccination Vaccine Gene 111

Delveinsight

DECEMBER 16, 2020

Caused by bacteria, viruses, and parasites, Sexually transmitted diseases (STDs) are a global health burden and it seems they are likely to maintain their status of being so in coming years also, primarily due to the lack of knowledge, and awareness. The medications can cure some of the STDs caused by bacteria, yeast, or parasites.

Bacteria 52

Bacteria Development Genotype Vaccine 52